transplant
tissu
donor
recipi
fundament
part
medicin
today
rang
tissu
includ
bone
skin
tendon
heart
valv
cornea
etc
collect
suitabl
donor
transplant
patient
tissu
transplant
would
clinic
benefit
manner
blood
transfus
transplant
without
risk
one
import
risk
transmiss
infecti
diseas
via
transplant
transplant
transmit
infect
tti
although
clear
tissu
carri
risk
distinct
easili
quantifi
tissu
treat
way
term
infecti
diseas
screen
appli
thu
way
blood
donat
tissu
donat
must
screen
infecti
diseas
prior
releas
clinic
use
although
basic
principl
appli
screen
tissu
donat
blood
donat
type
donat
biolog
product
import
differ
blood
tissu
donat
result
differ
actual
screen
strategi
appli
firstli
importantli
sourc
tissu
donat
includ
live
deceas
cadaver
donor
secondli
whilst
specif
infecti
agent
screen
broadli
specif
marker
infect
use
individu
infecti
agent
may
differ
fundament
issu
consid
screen
tissu
donat
transmiss
infecti
agent
tia
statu
donor
live
deceas
screen
tissu
collect
live
donor
tia
effect
differ
screen
blood
donat
blood
sampl
use
screen
collect
normal
venepunctur
live
individu
characterist
sampl
ident
screen
perform
use
assay
specif
design
develop
suppli
test
blood
sampl
collect
live
individu
screen
tissu
deceas
donor
blood
sampl
collect
postmortem
non
heart
beat
present
specif
problem
need
overcom
ensur
accur
reliabl
screen
result
problem
surround
overal
qualiti
sampl
obtain
valid
suitabl
substrat
assay
use
time
postmortem
collect
integr
sampl
volum
level
haemolysi
biochem
chang
postmortem
etc
howev
long
problem
acknowledg
dealt
resolv
right
way
overal
qualiti
screen
programm
whether
sampl
collect
screen
tissu
donat
live
deceas
donor
similarli
screen
donor
donor
select
process
also
determin
natur
donor
select
process
appli
live
donor
similar
appli
blood
donor
except
donor
gener
volunt
way
altruist
blood
donor
live
tissu
donor
may
often
approach
directli
direct
histori
may
therefor
taken
howev
case
deceas
donor
although
process
histori
second
hand
may
total
correct
accur
thu
inher
risk
associ
deceas
tissu
donat
must
necessarili
higher
live
donat
screen
strategi
develop
accordingli
text
look
screen
tissu
donat
rang
infecti
agent
may
present
donor
time
collect
tissu
therefor
like
present
donat
collect
consequ
like
transmit
transplant
donat
tissu
agent
includ
virus
bacteria
parasit
prion
subject
bacterialfung
contamin
tissu
product
result
collect
process
storag
process
cover
particular
text
infecti
agent
tissu
donat
need
screen
essenti
blood
donat
specif
marker
use
screen
target
individu
infecti
agent
howev
may
infecti
agent
addit
marker
may
includ
increas
sensit
screen
tabl
list
rang
infecti
agent
report
transmit
via
blood
blood
product
although
agent
report
transmit
via
tissu
transplant
reason
consid
agent
could
would
transmit
present
tissu
donor
donat
tissu
thu
approach
term
identifi
specif
donor
risk
need
follow
albeit
obviou
issu
preselect
deceas
donor
actual
transmiss
infecti
agent
specif
interest
consid
three
categori
tissu
donat
must
screen
mandatori
recognis
commonli
encount
threat
specif
donat
need
screen
specif
identifi
riskdiscretionari
uk
terminolog
rare
unknown
threat
dealt
casebycas
basi
other
addit
defin
infecti
agent
specif
target
marker
infect
infecti
agent
must
also
defin
avail
target
vari
accord
infecti
agent
theoret
alway
target
infecti
agent
howev
suitabl
target
context
screen
low
risk
donor
consid
perspect
biolog
agent
host
respons
infect
sensit
predict
avail
test
timefram
appear
differ
marker
agent
use
marker
term
reliabl
detect
infect
determin
prerequisit
effect
screen
programm
alway
thorough
understand
biolog
agent
cours
infect
host
even
though
could
argu
tissu
product
process
way
remov
inactiv
infecti
agent
could
theoret
present
use
tissu
product
collect
donor
may
infect
consid
appropri
practic
irrespect
process
method
use
pathogen
inactiv
remov
method
consid
total
effect
therefor
must
use
conjunct
instead
screen
donor
known
infect
transmiss
infecti
agent
clear
risk
transmiss
therefor
product
releas
clinic
use
infecti
agent
current
consid
mandatori
screen
tissu
blood
donat
countri
develop
healthcar
system
human
tcell
lymphotrop
virus
iii
htlv
treponema
pallidum
caus
agent
syphili
infecti
agent
publish
irrefut
evid
transmiss
blood
bodi
fluid
therefor
potenti
transmiss
residu
blood
tissu
product
agent
gener
present
popul
worldwid
although
preval
incid
vari
significantli
countri
countri
present
gener
risk
theori
donor
could
infect
irrespect
absenc
known
risk
symptom
import
understand
risk
someth
predon
question
select
process
seek
identifi
donor
may
expos
infecti
agent
rout
awar
addit
infecti
agent
produc
asymptomat
subclin
chronic
infect
donor
may
appear
fit
well
time
donat
whilst
infect
thu
infecti
especi
import
screen
cadaver
donor
obvious
question
directli
select
process
depend
upon
famili
close
contact
believ
may
necessarili
truth
donat
therefor
theoret
risk
infect
one
agent
blanket
screen
donat
necessari
howev
mention
well
identifi
infecti
agent
specif
screen
target
infecti
agent
must
identifi
tabl
list
specif
screen
target
mandatori
screen
requir
donat
collect
uk
blood
servic
infecti
agent
screen
consid
discretionari
ie
donat
requir
screen
compris
agent
publish
irrefut
evid
transmiss
blood
bodi
fluid
caus
signific
diseas
risk
easili
mitig
agent
endem
natur
present
gener
popul
countri
particular
risk
factor
infect
specif
identifi
donor
specif
exampl
infecti
agent
defin
discretionari
west
nile
viru
wnv
plasmodium
spp
caus
agent
malaria
trypanosoma
cruzi
caus
agent
chaga
diseas
consid
potenti
risk
absolut
requir
exposur
donor
viru
wnv
parasit
plasmodium
trypanosoma
either
live
visit
endem
area
donor
risk
therefor
easili
specif
identifi
point
donat
donat
donor
requir
addit
screen
addit
well
known
characteris
commonli
screen
infecti
agent
alway
potenti
transmiss
infecti
agent
may
exist
agent
gener
low
preval
incid
often
tightli
geograph
restrict
rare
transmit
nonetheless
may
transmit
present
donor
time
donat
may
emerg
agent
transmiss
rare
transmit
past
incid
preval
start
increas
either
increas
incid
endem
countri
spread
previous
nonendem
countri
increas
travel
endem
countri
may
yet
unidentifi
infecti
agent
would
transmiss
time
appear
caus
identifi
transfus
transplant
associ
infect
tabl
consid
baselin
list
infecti
agent
known
present
threat
report
blood
transfus
transmiss
although
agent
list
transmit
blood
may
sever
transmiss
hand
case
global
especi
exot
agent
list
howev
provid
definit
list
possibl
current
futur
infecti
threat
clearli
imposs
term
potenti
candid
agent
meet
follow
criteria
would
identifi
particular
agent
could
transmit
tissu
transplant
present
donor
time
donat
consid
viabl
threat
agent
must
present
donat
tissu
infecti
form
stabl
donat
tissueprocess
process
storag
condit
normal
requir
product
circul
donor
point
collect
tissu
yet
without
give
rise
identifi
symptom
donor
narrow
field
somewhat
must
made
clear
everi
infecti
agent
afflict
man
potenti
transfusiontransplant
threat
inde
number
potenti
threat
small
proport
infecti
agent
current
known
man
nonetheless
well
characteris
agent
whilst
major
concern
present
may
spread
current
nonendem
area
therefor
need
monitor
includ
virus
sar
chikungunya
viru
lymphocyt
choriomening
viru
lcmv
parasit
leishmania
spp
one
major
problem
may
influenc
screen
programm
infecti
agent
potenti
limit
either
appropri
screen
target
avail
andor
correspond
screen
test
avail
may
significantli
hinder
impact
abil
develop
effect
appropri
screen
strategi
agent
result
greater
relianc
donor
exclus
rather
invitro
screen
someth
alway
possibl
effect
cadaver
donorsdon
sever
acut
respiratori
syndrom
sar
respiratori
infect
caus
recent
emerg
coronaviru
sarscov
diseas
sever
morbid
mortal
present
nonspecif
sign
symptom
clearcut
diagnost
approach
prospect
identifi
case
prior
appear
symptom
viru
viraem
phase
day
preced
symptom
persist
symptomat
phase
viraem
individu
may
transmit
blood
tissu
collect
earli
asymptomat
phase
infect
screen
individu
sarscov
possibl
use
molecular
techniqu
identif
deferr
donor
may
potenti
expos
viru
current
effect
way
minim
risk
transmiss
chikungunya
arboviru
virus
transmit
insect
transmit
primarili
mosquito
usual
aed
spp
ill
acut
symptomat
diseas
characterist
begin
rapid
onset
joint
pain
may
may
accompani
muscl
pain
high
fever
conjunct
rash
sever
ill
vari
tend
less
sever
children
infect
individu
recov
week
small
proport
may
residu
chronic
joint
pain
year
infect
usual
fatal
may
contribut
factor
death
patient
preexist
underli
diseas
diseas
occur
throughout
africa
asia
part
southern
europ
anywher
carrier
mosquito
speci
found
recent
number
outbreak
island
indian
ocean
one
particular
reunion
result
cessat
blood
collect
outbreak
pass
viru
viraem
phase
prior
symptomat
phase
viraem
individu
may
transmit
blood
tissu
collect
earli
presymptomat
phase
infect
screen
individu
chikungunya
possibl
use
molecular
techniqu
identif
deferr
donor
may
potenti
expos
viru
current
effect
way
minim
risk
transmiss
howev
overal
risk
transmiss
chikungunya
tissu
low
diseas
acut
onset
gener
highli
symptomat
case
import
chikungunya
record
uk
clear
histori
risk
clinic
symptom
lymphocyt
choriomening
viru
lcmv
viru
carri
rodent
caus
lymphocyt
choriomening
lcm
present
asept
mening
enceph
meningoenceph
although
infect
often
asymptomat
mild
febril
ill
diseas
rare
seriou
although
infect
pregnanc
lead
sever
diseas
infant
infect
commonli
acquir
contact
infect
rodent
often
household
pet
urin
drop
bed
etc
transmiss
also
occur
via
bite
open
wound
contact
contamin
materi
humantohuman
transmiss
report
except
vertic
transmiss
mother
foetu
howev
lcmv
identifi
transmit
organ
transplant
although
case
acut
lcm
donor
would
rare
event
screen
lcmv
infect
possibl
molecular
screen
would
need
identifi
viraem
donor
leishmaniasi
parasit
diseas
found
part
tropic
subtrop
southern
europ
caus
infect
leishmania
parasit
spread
bite
infect
sand
fli
sever
differ
form
leishmaniasi
human
common
form
cutan
caus
skin
sore
viscer
kala
azar
affect
intern
organ
eg
spleen
liver
bone
marrow
factor
determin
form
diseas
includ
leishmani
speci
geograph
locat
immun
respons
host
although
gener
symptomat
asymptomat
infect
occur
possibl
parasitaem
individu
present
blood
tissu
donor
although
report
case
transmiss
blood
tissu
screen
leishmaniasi
straightforward
antibodi
respons
may
low
absent
cutan
case
although
screen
possibl
use
molecular
techniqu
howev
identif
deferr
donor
may
potenti
expos
viru
current
effect
way
minim
risk
transmiss
effect
invitro
screen
requir
effect
screen
strategi
develop
ensur
test
perform
target
correctli
outcom
use
effect
appropri
probabl
first
issu
consid
develop
strategi
screen
tissu
donat
fact
tissu
donat
divid
live
donor
surgic
tissu
deceas
donor
deceas
tissu
fundament
differ
origin
tissu
thu
approach
avail
screen
donor
mean
two
consid
separ
separ
strategi
develop
whilst
core
screen
need
essenti
obviou
restrict
donor
select
process
appli
deceas
donor
mean
much
greater
relianc
invitro
laboratori
test
determin
safeti
tissu
collect
case
surgic
tissu
howev
donor
treat
virtual
way
blood
donor
formal
donor
select
process
prior
donat
identifi
specif
risk
determin
overal
suitabl
donor
sourc
tissu
donat
although
laboratori
test
still
final
decid
releas
donat
clinic
use
experi
select
blood
donor
shown
valu
donor
select
process
reduc
risk
collect
donat
high
risk
donor
name
donor
may
recent
infect
infecti
infect
may
detect
time
test
use
window
period
two
basic
element
screen
strategi
firstli
defin
infecti
agent
individu
specif
screen
target
infecti
agent
secondli
actual
test
algorithm
adopt
discuss
rang
infecti
agent
need
consid
ensur
tissu
safeti
similar
blood
gener
well
defin
likewis
specif
screen
target
infecti
agent
also
well
defin
howev
target
may
differ
depend
upon
rel
inher
risk
associ
differ
donat
type
case
tissu
deceas
surgic
addit
screen
ad
inher
risk
higher
tabl
outlin
mandatori
screen
requir
blood
tissu
stem
cell
donat
collect
process
within
uk
transfus
servic
although
common
core
quit
differ
addit
requir
differ
donat
type
defin
specif
screen
target
therefor
fundament
part
screen
strategi
reflect
specif
infect
risk
donor
popul
tissu
collect
second
key
element
screen
strategi
actual
screen
algorithm
adopt
algorithm
essenti
defin
screen
assay
use
term
initi
repeat
test
final
screen
result
determin
area
similar
blood
screen
algorithm
use
blood
screen
appli
equal
tissu
donat
screen
howev
essenti
defin
appropri
algorithm
particular
screen
perform
blood
tissu
screen
may
diverg
realli
three
possibl
algorithm
use
screen
donat
lowrisk
donor
popul
determin
fate
ie
suitabl
use
discard
algorithm
initi
screen
test
assay
use
result
obtain
determin
donat
fate
neg
suitabl
clinic
use
reactivediscard
donat
algorithm
initi
screen
test
assay
repeat
initi
reactiv
duplic
use
test
use
rule
ident
result
result
obtain
consid
true
screen
result
determin
donat
fate
neg
suitabl
clinic
use
reactivediscard
algorithm
initi
screen
test
assay
repeat
initi
reactiv
duplic
use
differ
screen
assay
assay
b
use
rule
determin
donat
fate
neg
suitabl
clinic
use
reactiv
discard
algorithm
clearli
quit
differ
differ
use
depend
upon
type
donat
screen
level
infect
donor
popul
complex
effect
qualiti
manag
system
although
algorithm
effect
ensur
similar
level
product
safeti
associ
specif
perhap
interest
relev
deal
tissu
donat
importantli
screen
algorithm
sensit
take
approach
respect
initi
screen
accept
screen
neg
donat
suitabl
releas
clinic
use
differ
sensit
sole
due
sensit
screen
assay
use
case
blood
donat
algorithm
one
use
major
transfus
servic
countri
develop
healthcar
system
offer
effect
approach
accept
level
specif
although
everi
donat
valuabl
appropri
point
blood
donat
numer
tissu
donat
donor
donat
regularli
far
easier
replenish
stock
thu
specif
screen
algorithm
whilst
import
critic
blood
donat
algorithm
use
reflect
inde
countri
use
algorithm
unnecessari
wastag
blood
donat
even
higher
howev
case
tissu
donat
especi
deceas
donat
singl
cadav
could
provid
signific
number
differ
tissu
specif
screen
algorithm
far
greater
signific
repeat
screen
reactiv
would
result
discard
product
even
reactiv
could
subsequ
proven
confirmatori
test
nonspecif
algorithm
base
upon
use
second
assay
assay
b
least
equal
sensit
assay
use
test
initi
screen
reactiv
algorithm
base
fact
nonspecif
reactiv
assay
specif
thu
major
nonspecif
reactiv
seen
assay
unlik
seen
assay
b
whilst
true
reactiv
alway
seen
assay
algorithm
increas
specif
screen
significantli
reduc
unnecessari
loss
donat
reactiv
assay
gener
infect
like
confirm
howev
algorithm
challeng
technic
qualiti
manag
perspect
algorithm
felt
advantag
mass
screen
environ
screen
blood
donat
major
issu
lot
tissu
donat
collect
test
process
transfus
servic
screen
approach
use
develop
blood
donat
may
optim
donat
type
especi
deceas
donat
thu
consider
must
given
implement
appropri
algorithm
product
type
rather
blanket
use
algorithm
primarili
design
blood
donat
lower
level
specif
may
accept
particularli
critic
deceas
tissu
donat
sampl
collect
postmortem
optimum
substrat
screen
assay
use
overal
specif
screen
may
lower
blood
donat
screen
although
number
author
report
problem
specif
deceas
screen
programm
deceas
tissu
screen
programm
current
place
within
english
nation
blood
servic
encount
level
screen
reactiv
overal
specif
screen
programm
rel
high
qualiti
blood
sampl
use
screen
tissu
donat
clearli
import
poor
qualiti
sampl
produc
poor
qualiti
result
potenti
result
loss
sensit
andor
specif
first
issu
consid
definit
qualiti
appli
blood
sampl
collect
purpos
screen
tissu
donat
releas
clinic
use
differ
deceas
surgic
tissu
import
sampl
qualiti
consid
includ
attribut
may
influenc
overal
reliabl
accuraci
screen
result
obtain
importantli
includ
condit
sampl
includ
age
constitu
sampl
repres
volum
import
issu
donor
sampl
id
etc
outsid
scope
particular
chapter
differ
deceas
surgic
tissu
donat
import
relat
sampl
qualiti
invitro
screen
blood
sampl
collect
surgic
donor
collect
live
heartbeat
individu
thu
normal
sampl
type
screen
assay
design
use
also
alway
suffici
volum
screen
requir
therefor
screen
surgic
donat
notwithstand
previou
discuss
specif
perform
use
system
approach
use
blood
donat
differ
natur
blood
sampl
collect
reliabl
accuraci
result
obtain
unlik
sampl
live
donor
blood
sampl
deceas
tissu
donor
unless
sampl
collect
whilst
donor
still
heartbeat
expect
necessarili
behav
way
heartbeat
individu
therefor
screen
perform
result
obtain
consid
care
valid
establish
key
issu
howev
much
fact
blood
sampl
cadav
rather
repres
sampl
suitabl
use
screen
assay
use
therefor
abil
fulli
reflect
infecti
diseas
statu
donor
natur
blood
sampl
collect
cadav
present
major
challeng
blood
sampl
collect
postmortem
may
differ
collect
antemortem
number
reason
sampl
collect
static
fluid
settl
cellular
liquid
phase
coagul
may
occur
result
biochem
chang
includ
red
cell
damag
cell
death
take
place
releas
wide
rang
cell
chemic
surround
tissu
fluid
overal
result
may
gross
haemolysi
andor
chang
blood
collect
includ
degrad
screen
target
would
present
blood
infect
individu
andor
releas
substanc
may
inhibitori
screen
assay
use
howev
chang
occur
postmortem
obvious
vari
cadav
depend
upon
factor
age
caus
death
time
death
coldstorag
cadav
time
premortem
direct
clinic
care
intervent
use
underli
condit
debar
tissu
donat
time
postmortem
sampl
collect
thu
occurr
postmortem
chang
per
se
necessarili
make
sampl
collect
less
suitabl
substrat
screen
screen
postmortem
sampl
deceas
tissu
donor
perform
mani
year
mani
countri
known
advers
outcom
addit
assay
valid
use
deceas
sampl
inde
commerci
avail
infecti
diseas
screen
assay
bloodborn
virus
undergon
limit
valid
work
manufactur
result
inclus
claim
assay
use
screen
deceas
sampl
collect
certain
condit
import
factor
screen
deceas
sampl
time
postmortem
sampl
collect
clearli
sooner
death
sampl
taken
less
like
effect
postmortem
chang
interestingli
howev
current
publish
paper
look
critic
time
postmortem
sampl
collect
regulatori
requir
within
eu
requir
sampl
collect
within
hour
postmortem
us
expect
tissu
would
collect
soon
possibl
postmortem
within
hour
current
subject
specif
regul
publish
studi
aspect
deceas
test
includ
sampl
collect
hour
postmortem
without
problem
encount
specif
studi
sampl
suitabl
relat
time
collect
lack
addit
problem
possibl
haemodilut
often
deceas
donor
lifesupport
system
prior
death
may
involv
either
volum
replac
rang
inert
volum
expand
transfus
case
potenti
dilut
constitu
patient
blood
therefor
reduc
repres
sampl
term
reflect
true
statu
donor
immedi
premortem
histori
donor
must
known
likelihood
advers
effect
due
haemodilut
least
sampl
collect
site
chosen
tri
minimis
risk
collect
sampl
contain
signific
amount
resuscit
fluid
report
case
failur
screen
identifi
hiv
infect
tissu
donor
specif
massiv
fluid
infus
shortli
death
result
dilut
hiv
antibodi
detect
interestingli
antibodi
level
return
normal
seen
detect
hour
later
tissu
fluid
natur
redistribut
howev
studi
perform
indic
modern
screen
assay
use
toler
signific
dilut
plasma
approach
point
fals
neg
result
may
occur
situat
like
occur
follow
signific
acut
blood
loss
fact
appar
assess
potenti
deceas
donor
fda
guidelin
seek
help
clarifi
situat
requir
tissu
bank
develop
algorithm
determin
degre
haemodilut
action
taken
term
valid
screen
result
within
nhsbt
clear
algorithm
follow
case
haemodilut
occur
enabl
degre
haemodilut
thu
sampl
suitabl
assess
actual
physic
process
obtain
sampl
cadav
differ
sampl
volum
often
major
challeng
perform
screen
requir
describ
blood
settl
across
cadav
peripheri
larger
vessel
cell
settl
fluid
compon
suitabl
site
sampl
collect
must
therefor
identifi
suitabl
depend
number
factor
includ
presenc
suitabl
volum
fluid
vessel
access
vessel
facilit
sampl
collect
probabl
result
damag
tissu
interest
exampl
sampl
collect
cardiac
stab
collect
process
must
ensur
suitabl
sampl
obtain
ie
suffici
serumplasma
abl
perform
screen
test
requir
addit
possibl
bacteri
contamin
sampl
tissu
either
due
bacteria
alreadi
present
cadav
collect
process
must
alway
consid
howev
grossli
bacteri
contamin
sampl
usual
obviou
suitabl
sampl
question
although
bacteri
contamin
tissu
prior
retriev
would
easili
identifi
also
concern
exampl
sampl
obtain
cardiac
stab
one
may
damag
valveintroduc
infect
site
thu
although
postmortem
sampl
deceas
tissu
donor
may
optimum
substrat
screen
assay
use
collect
care
control
condit
sampl
collect
may
resembl
obtain
heartbeat
individu
postmortem
chang
would
advers
effect
screen
perform
certainli
major
approxim
samplesyr
refer
author
laboratori
singl
nation
laboratori
respons
screen
deceas
tissu
donat
collect
within
nh
blood
transplant
nhsbt
also
provid
screen
servic
nonnhsbt
tissu
bank
suitabl
screen
give
rise
problem
beyond
slightli
lower
overal
specif
thu
whilst
sampl
collect
postmortem
deceas
tissu
donor
suitabl
substrat
mani
screen
assay
collect
condit
must
properli
control
ensur
repres
premortem
sampl
serolog
statu
donor
possibl
addit
screen
system
develop
must
specif
design
gener
reliabl
accur
result
possibl
group
sampl
invitro
laboratori
screen
perform
divid
serolog
molecular
abl
understand
specif
role
valu
two
differ
approach
basic
biolog
infect
must
understood
follow
exposur
infecti
agent
period
infecti
agent
either
enter
bodi
cell
start
replic
captur
elimin
bodi
passiv
defenc
mechan
agent
enter
bodi
cell
start
replic
highli
like
product
infect
follow
period
infecti
agent
continu
replic
local
suffici
start
spread
suitabl
target
site
within
bodi
time
level
low
gener
detect
howev
agent
start
spread
gener
via
circul
level
high
enough
detect
point
nucleic
acid
start
detect
depend
upon
infecti
agent
antigen
may
also
detect
subsequ
agent
spread
immun
respons
initi
symptom
appear
antibodi
level
start
rise
becom
detect
howev
depend
upon
agent
point
nucleic
acid
level
circul
may
start
fall
immun
system
start
combat
infect
balanc
ensu
case
major
blood
born
infecti
agent
infecti
agent
sequest
prefer
cell
bodi
chronic
longterm
infect
develop
antibodi
produc
simpli
indic
infect
time
possibl
mediat
infect
necessarili
confer
immun
agent
case
infecti
agent
give
rise
acut
infect
appear
antibodi
circul
mark
start
resolut
infect
clearanc
agent
bodi
subsequ
immun
least
short
period
particular
infecti
agent
serolog
screen
describ
convent
approach
look
presenc
specif
serolog
maker
infect
blood
sampl
collect
donor
approach
use
mani
year
offer
sensit
reliabl
fulli
processcontrol
costeffect
screen
identifi
vast
major
donor
genuin
infect
earli
recent
ongo
old
infect
serolog
screen
rel
cheap
although
requir
dedic
often
specif
equip
equip
particularli
hightech
particularli
expens
consid
work
rate
achiev
overal
reliabl
molecular
screen
recent
origin
rel
recent
appli
mass
donat
screen
programm
inde
mass
screen
applic
still
develop
current
bespok
screen
system
primarili
design
blood
rather
donat
type
molecular
screen
target
genom
materi
infecti
agent
work
cyclic
amplif
low
level
target
normal
undetect
high
level
easili
detect
offer
theoret
higher
sensit
serolog
screen
identif
earli
infect
time
less
effect
detect
existingold
infect
thu
molecular
screen
consid
addit
replac
serolog
screen
addit
rel
expens
compar
serolog
hightech
approach
utilis
new
develop
technolog
requir
dedic
specialist
equip
autom
mass
screen
donat
requir
mani
countri
major
question
still
address
whether
cost
molecular
screen
justifi
increment
benefit
molecular
screen
serolog
alon
serolog
screen
perform
look
presenc
specif
serolog
marker
infecti
agent
found
blood
result
infect
marker
either
specif
antigen
produc
infecti
agent
gener
appear
surfac
agent
case
may
express
infect
cell
andor
specif
antibodi
produc
individu
immun
system
respons
infect
tabl
outlin
serolog
marker
tissu
donat
collect
within
uk
transfus
servic
screen
although
immun
respons
infecti
agent
often
associ
protect
immun
inde
whole
purpos
vaccin
stimul
bodi
immun
respons
produc
protect
antibodi
respect
major
blood
born
infecti
agent
transmiss
blood
tissu
except
case
hbsab
protect
neutralis
antibodi
presenc
antibodi
indic
protect
rather
indic
infect
presenc
infecti
agent
individu
common
import
featur
relev
bloodborn
infecti
agent
persist
infect
gener
resolv
natur
although
approxim
case
hcv
resolv
individu
serolog
indistinguish
persist
infect
thu
presenc
hcv
antibodi
differenti
infect
versu
immun
number
differ
type
immunoassay
avail
broadli
principl
howev
suitabl
screen
cadaver
sampl
often
due
technic
sampl
sampl
rather
scientif
issu
gener
immunoassay
compris
solid
phase
liquid
phase
assay
perform
number
stage
incub
period
wash
remov
excess
materi
end
incub
solid
phase
carri
immobilis
compon
assay
design
captur
specif
target
may
may
present
liquid
phase
sampl
microwel
format
assay
well
coat
either
antigen
ag
antibodi
ab
depend
specif
target
ag
detect
ab
ab
detect
ag
captur
target
detect
use
conjug
detect
agab
complex
form
enzym
attach
enzym
trigger
colour
reagent
signal
presenc
conjug
thu
target
develop
colour
measur
assay
use
today
detect
antigen
antibodi
either
singli
combin
depend
particular
infecti
agent
highli
sensit
specif
immunoassay
design
detect
specif
target
earli
possibl
infect
process
run
autom
platform
high
level
process
control
ensur
highli
accur
reproduc
result
thu
overal
reliabl
screen
process
howev
time
aspect
also
problem
certainli
case
deceas
sampl
autom
screen
platform
design
specif
screen
blood
donat
primarili
autom
sampl
detect
system
rather
assay
exampl
haemolys
low
volum
slightli
dilut
sampl
reject
unsuit
process
identifi
previous
surgic
tissu
donat
align
virtual
complet
blood
donat
sampl
collect
live
individu
thu
gener
good
qualiti
sampl
optimum
system
wherea
deceas
sampl
commonli
reject
system
fail
detect
properli
system
therefor
sampl
test
time
littl
option
use
separ
screen
strategi
deceas
sampl
use
assay
system
use
specif
valid
screen
deceas
sampl
two
potenti
perform
issu
need
consid
screen
programm
may
relev
serolog
screen
specif
serolog
screen
deceas
donat
sensit
specif
past
major
report
issu
specif
serolog
screen
deceas
donat
mani
author
report
high
reactiv
rate
serolog
screen
assay
use
consequ
high
loss
donat
whilst
true
deceas
sampl
present
challeng
perform
serolog
screen
mainli
visibl
poor
qualiti
experi
specif
screen
assay
problem
report
rather
concern
overal
sensit
screen
programm
import
assay
use
valid
specif
use
deceas
sampl
determin
specif
issu
sensit
issu
problem
specif
issu
seen
high
screen
reactiv
rate
subsequ
confirm
wast
affect
safeti
howev
sensit
issu
would
seen
infect
donat
transplant
recipi
infect
thu
import
part
assay
evalu
valid
screen
deceas
blood
sampl
demonstr
deceas
natur
sampl
reduc
sensit
assay
unfortun
present
problem
suitabl
cadaver
sampl
simpli
avail
indirect
method
use
molecular
screen
perform
detect
presenc
blood
nucleic
acid
transmiss
infecti
agent
presenc
viral
nucleic
acid
specif
indic
presenc
viru
case
infect
time
infecti
agent
target
molecular
screen
hepat
b
viru
hbv
dna
hepat
c
viru
hcv
rna
human
immunodefici
viru
hiv
rna
one
particular
product
human
cytomegaloviru
hcmv
dna
tabl
outlin
viral
nucleic
acid
tissu
donat
collect
within
uk
transfus
servic
screen
essenti
molecular
screen
use
detect
low
level
viru
broken
two
element
extract
purif
nucleic
acid
sampl
subsequ
specif
amplif
detect
target
nucleic
acid
present
although
viral
nucleic
acid
may
present
sampl
donor
even
thousand
genom
copi
present
overal
amount
nativ
nucleic
acid
present
still
far
small
abl
detect
directli
technolog
current
avail
instead
approach
taken
isol
nucleic
acid
present
sampl
amplifi
specif
target
may
present
level
detect
either
direct
visualis
use
nucleic
acid
bind
fluoresc
dye
enzym
action
gener
chemiluminesc
signal
proport
amount
nucleic
acid
present
current
main
molecular
methodolog
use
molecular
screen
donat
infecti
agent
polymeras
chain
reaction
pcr
transcript
mediat
amplif
tma
although
chapter
appropri
place
provid
indepth
review
methodolog
overview
follow
pcr
temperatur
depend
method
allow
exponenti
amplif
short
dna
sequenc
present
within
longer
doublestrand
dna
molecul
case
genom
infecti
agent
screen
entail
use
pair
primer
short
sequenc
nucleotid
complementari
defin
sequenc
two
strand
dna
primer
extend
dna
polymeras
copi
made
target
sequenc
make
copi
primer
use
make
anoth
copi
input
sequenc
also
short
copi
made
first
round
synthesi
lead
logarithm
amplif
rna
virus
rna
must
copi
dna
first
use
revers
transcriptas
rt
step
tma
isotherm
method
allow
exponenti
amplif
rna
dna
target
pcr
genom
infecti
agent
screen
tma
technolog
use
two
primer
one
contain
promot
sequenc
rna
polymeras
two
enzym
rna
polymeras
revers
transcriptas
first
step
amplif
primer
promot
sequenc
hybrid
target
rrna
defin
site
revers
transcriptas
creat
dna
copi
target
rrna
extens
end
promot
primer
rna
result
rna
dna
duplex
degrad
rnase
activ
revers
transcriptas
second
primer
bind
dna
copi
new
strand
dna
synthesis
end
primer
revers
transcriptas
creat
doublestrand
dna
molecul
rna
polymeras
recognis
promot
sequenc
dna
templat
initi
transcript
newli
synthesis
rna
amplicon
reenter
tma
process
serv
templat
new
round
replic
pcr
lead
logarithm
amplif
howev
molecular
screen
still
emerg
approach
much
underli
technolog
use
research
develop
activ
year
recent
technolog
success
develop
fulli
autom
mass
screen
system
includ
sampl
prepar
molecular
aspect
provid
result
h
howev
although
degre
sampl
qualiti
still
factor
consid
although
design
work
rang
differ
sampl
type
initi
sampl
handl
side
autom
system
may
way
serolog
system
reject
unsuit
sampl
detect
reject
sampl
detect
system
howev
molecular
techniqu
distinct
advantag
serolog
sampl
intern
control
ad
prior
nucleic
acid
extract
process
extract
amplifi
concurr
specif
target
may
present
detect
use
separ
detect
system
thu
everi
sampl
score
posit
intern
control
irrespect
presenc
specif
target
interest
uniqu
valid
neg
result
failur
intern
control
indic
failur
process
point
whether
due
failur
molecular
reagent
due
inhibit
reagent
someth
within
sampl
invalid
result
sampl
discuss
previous
valu
molecular
screen
primarili
detect
earli
infect
donor
recent
infect
later
infect
serolog
marker
present
far
easier
demonstr
assay
significantli
less
expens
molecular
assay
import
question
determin
increas
valu
provid
includ
molecular
screen
addit
serolog
screen
although
molecular
screen
theoret
offer
earlier
detect
infect
actual
valu
much
relat
biolog
individu
infecti
agent
overal
perform
serolog
screen
incid
infect
popul
antigen
assay
avail
gener
limit
addit
valu
molecular
screen
unless
incid
infect
high
enough
indic
signific
number
donor
may
expos
agent
howev
lowrisk
popul
rare
case
howev
antibodi
assay
avail
window
period
infect
rel
long
molecular
screen
may
valu
howev
incid
infect
donor
popul
determin
mani
donor
would
like
detect
molecular
serolog
screen
low
risk
popul
actual
number
donor
would
detect
molecular
screen
serolog
screen
extrem
low
current
hcv
blood
donat
collect
within
nb
number
hcv
rna
posit
serolog
neg
donat
approxim
million
donat
ie
one
donat
per
year
current
donat
level
overal
effect
serolog
screen
tissu
donat
surgic
deceas
without
question
mani
year
serolog
screen
approach
avail
screen
tissu
donat
publish
evid
except
case
haemodilut
approach
led
transmiss
infect
result
serolog
test
fail
detect
presenc
serolog
marker
infect
individu
inclus
molecular
test
least
theoret
increas
level
safeti
even
although
increment
benefit
gain
serolog
screen
alon
difficult
imposs
quantifi
accur
due
rel
small
number
tissu
donat
screen
even
smaller
number
confirm
posit
donor
virtual
imposs
accur
determin
incid
infect
tissu
donor
overal
microbiolog
safeti
tissu
donat
properli
effect
screen
infecti
diseas
least
equal
blood
donat
unfortun
howev
laboratori
test
perfect
occas
number
reason
test
may
detect
target
consequ
screen
programm
absolut
sensit
possibl
infect
donor
could
undetect
result
entri
infect
donat
suppli
chain
refer
residu
risk
ie
risk
infect
screen
neg
donat
howev
gener
due
lack
detect
target
rather
assay
fail
detect
target
brief
assay
fail
detect
target
either
assay
miss
someth
present
noth
present
assay
detect
although
donor
infect
donat
infecti
first
scenario
aris
either
due
poor
assay
perform
analyt
sensit
due
poor
perform
assay
operatorsystem
error
howev
well
evalu
valid
highli
sensit
assay
use
screen
perform
within
formal
well
design
qualiti
manag
system
well
train
compet
staff
scenario
rare
ever
occur
second
scenario
lack
detect
target
yet
infect
present
howev
like
occur
matter
good
screen
programm
qualiti
manag
system
relat
natur
histori
infect
individu
stage
normal
infect
process
major
threat
term
residu
risk
therefor
donor
infect
yet
neg
screen
normal
screen
target
present
present
detect
level
situat
occur
natur
earli
cours
infect
time
product
infect
arisen
specif
screen
target
either
produc
level
risen
detect
assay
use
also
occur
later
infect
infect
start
resolv
level
screen
target
declin
detect
yet
infect
remain
refer
window
period
infect
infecti
yet
undetect
screen
assay
use
rel
term
specif
antibodi
appear
later
cours
infect
antigen
antigen
later
nucleic
acid
therefor
screen
target
antibodi
period
time
donat
infect
donor
would
give
neg
screen
result
despit
presenc
antigen
associ
infect
appli
compar
antigen
without
antibodi
screen
molecular
screen
situat
rel
time
first
appear
nucleic
acid
first
appear
antigen
much
shorter
mani
instanc
appear
close
togeth
actual
measur
increment
benefit
obtain
use
molecular
screen
addit
antigen
antigenantibodi
screen
overal
risk
collect
donat
donor
may
window
period
infect
much
relat
overal
level
infect
popul
specif
incid
infect
donor
popul
higher
incid
infect
greater
risk
donor
could
recent
infect
time
abil
detect
infect
donat
depend
upon
effect
appropri
screen
programm
place
screen
programm
rel
poor
sensit
like
fail
detect
recent
infect
donor
howev
overal
risk
also
depend
upon
actual
number
donat
collect
although
incid
infect
may
blood
tissu
donor
popul
popul
similar
overal
number
tissu
donat
collect
mani
order
magnitud
lower
number
blood
donat
thu
argu
overal
probabl
actual
encount
donat
tissu
donor
window
period
assum
screen
programm
equal
greater
sensit
much
lower
blood
donat
howev
actual
number
infecti
identifi
uk
look
incid
confirm
infect
deceas
tissu
donor
significantli
higher
blood
donor
denomin
around
order
magnitud
less
therefor
figur
compar
directli
furthermor
significantli
patient
transfus
greater
number
potenti
exposur
therefor
necessarili
true
argu
tissu
higher
risk
blood
donat
window
period
thu
main
reason
today
donat
tissu
blood
associ
residu
albeit
low
risk
screen
programm
strategi
develop
ensur
window
period
reduc
short
period
possibl
overal
current
screen
tissu
donat
prior
releas
highli
effect
prevent
transmit
infect
basic
principl
appli
screen
blood
donat
appli
consider
overlap
need
identifi
low
risk
donor
rang
transmiss
infecti
diseas
screen
assay
use
screen
strategi
develop
certainli
littl
differ
screen
surgic
tissu
donat
blood
donat
sampl
collect
standard
venepunctur
live
individu
screen
deceas
tissu
donat
differ
inasmuch
natur
sampl
fundament
differ
although
screen
assay
reliabl
screen
process
relat
deceas
sampl
need
assur
particularli
repres
sampl
collect
respect
screen
result
obtain
reflect
true
statu
donor
therefor
donat
addit
consider
given
specif
screen
algorithm
use
commonli
use
blood
donat
screen
may
alway
offer
appropri
approach
screen
deceas
tissu
donat
issu
specif
someth
particular
relev
unnecessari
loss
tissu
donat
due
poor
specif
unaccept
tissu
product
gener
shorter
suppli
often
mani
potenti
recipi
wait
list
furthermor
cadav
may
provid
larg
number
differ
tissu
clinic
use
nonspecif
screen
result
would
result
loss
signific
number
clinic
valuabl
product
